Skip to main content
. 2017 Oct 4;35(32):3706–3713. doi: 10.1200/JCO.2017.73.3238

Fig 1.

Fig 1.

Enhancer of zeste homolog 2 (EZH2) immunohistochemical staining and Kaplan-Meier estimate of overall survival in independent analytic and validation cohorts. Representative images for EZH2 staining: (A) negative (≤ 8.7%) and (B) positive (> 8.7%) in renal cell carcinoma. Scale bar, 100 μM. (Original magnification, ×200; inset of representative nuclei, ×400.) Overall survival by EZH2 expression in (C) analytic and (D) validation cohorts.